ShadowGraph
Start free trial
SEC filings · customer concentration · AMPH

Amphastar Pharmaceuticals's major customers

McKesson accounted for 24% of Amphastar Pharmaceuticals's revenue in FY 2025, about the same as 25% a year earlier.

3major customers now
65%of revenue from them
0listed suppliers depending on it
2012–2026years covered
Free

Get an email when Amphastar Pharmaceuticals's customer concentration changes

When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.

We only use your address for this watch. Double opt-in, see our privacy notice.

Major customers of Amphastar Pharmaceuticals

Customers that Amphastar Pharmaceuticals named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.

CustomerShare of revenueChange vs prior yearHistoryLatest filing
McKessonMCK24%from 25%FY 2012: 27%FY 2013: 26%FY 2014: 22%FY 2015: 22%FY 2016: 21%FY 2017: 27%FY 2018: 27%FY 2019: 25%FY 2020: 22%FY 2021: 21%FY 2022: 22%FY 2023: 25%FY 2024: 25%FY 2025: 24%14 yearsFY 2025 · filed 26 Feb 2026
CencoraCOR22%from 20%FY 2021: 24%FY 2022: 23%FY 2023: 20%FY 2024: 20%FY 2025: 22%5 yearsFY 2025 · filed 26 Feb 2026
Cardinal HealthCAH19%from 19%FY 2012: 13%FY 2013: 13%FY 2014: 14%FY 2015: 17%FY 2016: 22%FY 2017: 23%FY 2018: 21%FY 2019: 22%FY 2020: 17%FY 2021: 16%FY 2022: 17%FY 2023: 15%FY 2024: 19%FY 2025: 19%14 yearsFY 2025 · filed 26 Feb 2026

Formerly disclosed

CustomerShare of revenueChange vs prior yearHistoryLatest filing
AmerisourceBergen23%last FY 2022FY 2012: 14%FY 2013: 15%FY 2014: 15%FY 2015: 17%FY 2016: 21%FY 2017: 28%FY 2018: 27%FY 2019: 24%FY 2020: 23%FY 2021: 24%FY 2022: 23%11 yearsFY 2022 · filed 1 Mar 2023
Allergan21%last FY 2015FY 2013: 35%FY 2014: 30%FY 2015: 21%3 yearsFY 2015 · filed 15 Mar 2016
Actavis14%last FY 2016FY 2012: 35%FY 2013: 35%FY 2014: 30%FY 2015: 21%FY 2016: 14%5 yearsFY 2016 · filed 15 Mar 2019
Eli Lilly AndLLY3%last FY 2024FY 2023: 8%FY 2024: 3%2 yearsFY 2024 · filed 3 Mar 2025
Mann KindMNKD3%last FY 2016FY 2014: 2%FY 2015: 8%FY 2016: 3%3 yearsFY 2016 · filed 15 Mar 2017

About this data

US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.

All companies · Latest dependency shifts · Bulk data and API